- Home
- IQV vs EQR Comparison
IQV vs EQR Comparison
Compare IQV & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IQV | EQR |
|---|---|---|
| Founded | 1982 | 1993 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9B | 24.3B |
| IPO Year | 2013 | 1994 |
Fundamental Metrics
Financial Performance| Metric | IQV | EQR |
|---|---|---|
| Price | $173.29 | $60.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 13 |
| Target Price | ★ $230.56 | $69.58 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.72% |
| EPS Growth | 4.67 | ★ 8.09 |
| EPS | ★ 7.84 | 2.94 |
| Revenue | ★ $9,739,000,000.00 | $2,701,075,000.00 |
| Revenue This Year | $6.77 | $4.17 |
| Revenue Next Year | $5.87 | $3.10 |
| P/E Ratio | $22.00 | ★ $20.27 |
| Revenue Growth | ★ 41.60 | 4.76 |
| 52 Week Low | $134.65 | $57.57 |
| 52 Week High | $247.05 | $72.40 |
Technical Indicators
Market Signals| Indicator | IQV | EQR |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 50.57 |
| Support Level | $157.59 | $58.62 |
| Resistance Level | $193.26 | $60.57 |
| Average True Range (ATR) | 5.86 | 1.10 |
| MACD | 1.87 | 0.15 |
| Stochastic Oscillator | 71.27 | 76.49 |
Price Performance
Historical ComparisonAbout IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.